Medifast (NYSE:MED) Updates Q4 2025 Earnings Guidance

Medifast (NYSE:MED) updated its fourth quarter 2025 earnings guidance on Monday. The company provided earnings per share guidance of -1.250–0.70 for the period, compared to the consensus earnings per share estimate of -0.230. The company issued revenue guidance of $65.0 million-$80.0 million, compared to the consensus revenue estimate of $85.1 million.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Medifast in a report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $16.50.

Medifast Trading Down 1.6%

NYSE:MED traded down $0.19 during mid-day trading on Monday, hitting $11.83. 175,041 shares of the company’s stock were exchanged, compared to its average volume of 209,198. Medifast has a fifty-two week low of $11.57 and a fifty-two week high of $21.98. The firm has a market capitalization of $130.02 million, a P/E ratio of 36.97 and a beta of 0.85. The company has a 50 day simple moving average of $13.57 and a 200-day simple moving average of $13.54.

Medifast (NYSE:MED) last released its quarterly earnings results on Monday, November 3rd. The specialty retailer reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.20). Medifast had a net margin of 0.76% and a return on equity of 2.00%. Medifast has set its Q4 2025 guidance at -1.250–0.70 EPS. As a group, analysts expect that Medifast will post 0.51 earnings per share for the current year.

Institutional Investors Weigh In On Medifast

A number of institutional investors have recently made changes to their positions in MED. Bank of America Corp DE lifted its stake in shares of Medifast by 37.4% in the second quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock worth $5,569,000 after acquiring an additional 107,854 shares during the period. AQR Capital Management LLC boosted its stake in shares of Medifast by 14.5% in the 1st quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer’s stock valued at $2,693,000 after purchasing an additional 25,366 shares during the last quarter. Man Group plc boosted its stake in shares of Medifast by 0.6% in the 2nd quarter. Man Group plc now owns 198,156 shares of the specialty retailer’s stock valued at $2,784,000 after purchasing an additional 1,200 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Medifast by 9.0% during the second quarter. Ameriprise Financial Inc. now owns 76,801 shares of the specialty retailer’s stock worth $1,079,000 after buying an additional 6,322 shares during the period. Finally, Bridgeway Capital Management LLC raised its stake in Medifast by 164.6% during the second quarter. Bridgeway Capital Management LLC now owns 57,944 shares of the specialty retailer’s stock worth $814,000 after buying an additional 36,044 shares during the last quarter. Institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.